Ixazomib

IFM 2018-02: ixazomib + daratumumab in elderly frail patients with R/R multiple myeloma

Results from the IFM 2014-01 trial: pomalidomide, dexamethasone & ixazomib in high-risk R/R myeloma

Alliance A061202: POM-DEX vs IXA-POM-DEX in R/R multiple myeloma

Long-term follow-up of the TOURMALINE-MM1 trial

The efficacy of ixazomib for the treatment of R/R myeloma

Novel agents and clinical trials emerging for the treatment of AL amyloidosis

Treatment options for transplant-ineligble myeloma patients: the promise of combination therapies

Managing multiple myeloma patients with del(17p)

Daratumumab in the treatment of high-risk MGUS and low-risk smoldering myeloma

Long-term follow-up results of TOURMALINE-MM2: IRd vs pbo-Rd in multiple myeloma

Tailored therapy in Waldenström’s macroglobulinemia

New therapies for amyloidosis

Overview of the final analysis of the Phase III TOURMALINE-MM1 trial

INSIGHT-MM: real-world analysis of DOT with Rd-based regimens in R/R myeloma

Final analysis of UVEA-IXA study of ixazomib in R/R myeloma

MRD evaluation during ixazomib maintenance in myeloma